New generation sequencing capabilities in determiningmutation status in chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease not only in the clinical course, immunophenotype of transformed B-lymphocytes (coexpression of CD5+ with CD19+ and CD20+ with CD23+), but also by genetic risk groups. Rapid progress in next generation sequencing technologies allows us to decipher the mutational status of the disease, the genetic and epigenetic variability of CLL, and evaluate its effect on the nature of the disease’s course. Identification of driver mutations allows us to expand our understanding of the pathogenesis of CLL and to select potential “targets” for therapy, contributing to the development and implementation of both new targeted drugs and their combinations